Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort

Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and b...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Fortner, RT, Sarink, D, Schock, H, Johnson, T, Tjønneland, A, Olsen, A, Overvad, K, Affret, A, His, M, Boutron-Ruault, MC, Boeing, H, Trichopoulou, A, Naska, A, Orfanos, P, Palli, D, Sieri, S, Mattiello, A, Tumino, R, Ricceri, F, Bueno-de-Mesquita, HB, Peeters, PH, Van Gils, CH, Weiderpass, E, Lund, E, Quirós, JR, Agudo, A, Sánchez, MJ, Chirlaque, MD, Ardanaz, E, Dorronsoro, M, Key, T, Khaw, KT, Rinaldi, S, Dossus, L, Gunter, M, Merritt, MA, Riboli, E, Kaaks, R
التنسيق:	Journal article
اللغة:	English
منشور في:	BioMed Central 2017

Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort

مواد مشابهة